Alendronate Sodium Tablets
Belongs to Category:
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
Product Description
Approval Number:
H20234225
Indications:
Suitable for the treatment of osteoporosis in postmenopausal women to prevent hip and spinal fractures (vertebral compression fractures). Suitable for the treatment of osteoporosis in men to increase bone mass.
Administration:
Treatment of Postmenopausal Osteoporosis:
Recommended dosage: 70 mg once weekly.
Treatment of Osteoporosis in Men to Increase Bone Mass:
Recommended dosage: One 70 mg tablet once weekly.
This product must be taken at least 30 minutes before the first food, beverage, or medication of the day, with plain water only, as other drinks (including mineral water), food, and certain medications may reduce its absorption.
It should be taken on the same fixed day each week, immediately upon waking in the morning. To ensure rapid delivery to the stomach and minimize esophageal irritation, the tablet should be swallowed with a full glass of plain water, and the patient must remain upright (avoid lying down) for at least 30 minutes after ingestion and before the first meal of the day. Do not take this medication at bedtime or before getting out of bed in the morning, as this increases the risk of esophageal adverse reactions .
All osteoporosis patients should receive calcium and vitamin D supplements if dietary intake is inadequate.
Elderly patients or those with mild to moderate renal impairment (creatinine clearance 35–60 mL/min) require no dosage adjustment. Due to insufficient clinical data, this product is not recommended for patients with severe renal impairment (creatinine clearance <35 mL/min).
If a dose is missed, the patient should take one tablet the next morning upon remembering and then resume the regular weekly schedule. Do not take two tablets on the same day.
The optimal duration of therapy has not been established. All patients receiving bisphosphonate treatment should undergo periodic evaluation to assess the need for continued therapy.
Patients with lower fracture risk may consider discontinuation after 3 to 5 years of treatment. After discontinuation, fracture risk should be reevaluated periodically.
Specifications:
70mg/tablet x 2 tablets/box
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
The main products cover cardiovascular diseases, diabetic complications, anti-tumor, calcium supplementation, digestive system, respiratory system, and orthopedics.
Related Products
Online Message
We will contact you within one business day. Please pay attention to your email.
Email: marcos.yuan@wangao.com.cn
Address: No. 688, Dinghai Road, Haimen City, Jiangsu Province
Mobile Version QR Code
WeChat Official Account
Copyright © 2025 Jiangsu Wangao Pharmaceutical Co., Ltd.